Evidence-supported steps including lowering BP targets to <130/80 mmHg, utilizing ambulatory monitoring, newer agents like aprocitentan, polypills, and renal denervation can improve hypertension control.
Addressing uncontrolled hypertension requires a comprehensive strategy encompassing stricter BP targets, enhanced monitoring, novel pharmacological agents, and device-based interventions.
Hypertension affects over 1.4 billion adults worldwide. Precise root cause analysis of suboptimal blood pressure control remains critically important for development of most optimal management strategies. We suggest the following evidence-supported steps can be immediately undertaken to improve uncontrolled hypertension treatment outcomes: reduction of the Medicare Quality Payment Program set blood pressure target to widely accepted goal of less than 130/80 mmHg, with the intent of providing additional cardiovascular benefits for senior US citizens; improving hypertension awareness and utilization of ambulatory blood pressure monitoring tools, as well as more frequent screening of uncontrolled patients for treatment noncompliance and/or therapeutic inertia; use of newer pharmaceutical agents in treatment of refractory hypertension, such as recently approved-agent aprocitentan; polypill treatment strategy encouragement, intending to improve poor medication compliance in the areas with challenging socioeconomic conditions; and timely consideration for RDN in multidrug-resistant and/or treatment-noncompliant patients.
Todua et al. (Tue,) conducted a editorial in Uncontrolled hypertension. Evidence-supported management strategies was evaluated. Evidence-supported steps including lowering BP targets to <130/80 mmHg, utilizing ambulatory monitoring, newer agents like aprocitentan, polypills, and renal denervation can improve hypertension control.